Cathie Wood’s ARK ETF adjusts portfolio, buys ABSCI, sells CRISPR

In the latest trading session, Cathie Wood’s ARK ETFs made several significant transactions as part of their ongoing portfolio adjustments. On Friday, July 25th, 2025, the most substantial trade came from the purchase of 2,248,226 shares of ABSCI CORP (NASDAQ:ABSI) through its ARKG ETF, with a total dollar value of $7,891,273. This purchase reflects ARK’s confidence in the biotech firm, known for its synthetic biology platform aimed at discovering and developing complex biological products.

Conversely, ARK took a bearish stance on CRISPR THERAPEUTICS AG (NASDAQ:CRSP), selling a combined total of 249,108 shares across its ARKK and ARKG ETFs, amounting to $16,456,074. This move signifies the largest dollar-value sale of the day and possibly indicates ARK’s reassessment of the gene-editing company’s near-term prospects.

ARK also divested from GUARDANT HEALTH INC (NASDAQ:GH) by selling 37,350 shares through its ARKG ETF, totaling $1,699,051. This follows a trend seen in the previous week, where ARK consistently reduced its holdings in the precision oncology company.

In communications, ARK displayed a bullish sentiment by buying 69,969 shares of IRIDIUM COMMUNICATIONS INC (NASDAQ:IRDM) spread across three of its ETFs—ARKK, ARKQ, and ARKX—for a total investment of $1,768,116. This purchase adds to a significant acquisition of IRIDIUM shares made just the day before, indicating a strategic accumulation of the stock.

Defense and security solutions provider KRATOS DEFENSE AND SECURITY SOLUTIONS INC (NASDAQ:KTOS) saw a sell-off by ARK, with 36,628 shares sold between the ARKQ and ARKX (NYSE:ARKX) ETFs, valued at $2,148,598. This follows a pattern of sales in KRATOS observed over the past week.

Additionally, ARK increased its stake in VERACYTE INC (NASDAQ:VCYT), a genomic diagnostics company, by purchasing 262,141 shares through its ARKK ETF at a dollar value of $6,183,906. This acquisition highlights ARK’s continued interest in the genomics sector.

Smaller transactions included the sale of 1,916 shares of VEEVA SYSTEMS INC (NYSE:VEEV) through its ARKG ETF, totaling $558,035. VEEVA SYSTEMS, which specializes in cloud-based software for the global life sciences industry, appears to be a less favored holding, given the modest size of the trade.

The trading activity demonstrated ARK’s dynamic investment approach, with significant moves in the biotech and health sectors, and continued interest in communications and genomics. Investors following ARK’s trades will note these shifts as they reflect ARK’s evolving market strategy and sector focus.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.